Anika Therapeutics Faces Investigation After Hyalofast Trial Misses Key Endpoints
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 55 minutes ago0mins
- Clinical Trial Results Underperform: Anika's July 30, 2025 announcement regarding its Hyalofast clinical trial indicated that while there were consistent improvements in pain and function, the study failed to meet its pre-specified primary endpoints, resulting in a 27.42% drop in share price to $8.10, reflecting investor concerns about the company's future prospects.
- Potential Management Violations: The law firm Kirby McInerney LLP is investigating whether Anika and its senior management may have violated federal securities laws or engaged in other unlawful business practices, which could further impact the company's reputation and shareholder confidence.
- COVID Impact on Study Results: The higher dropout rate in the microfracture arm and missed visits due to COVID led to a reduced evaluable sample size, complicating statistical analysis, which may raise questions about the company's research design and execution.
- Investor Rights Protection: Individuals who purchased or acquired Anika securities can contact Kirby McInerney LLP for more information, indicating that the company's legal liabilities in this matter may affect future investment decisions.
ANIK.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ANIK
Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.490
Low
16.00
Averages
16.00
High
16.00
Current: 9.490
Low
16.00
Averages
16.00
High
16.00
Barrington
Michael Petusky
Outperform
maintain
$15 -> $16
2025-11-06
Reason
Barrington
Michael Petusky
Price Target
$15 -> $16
2025-11-06
maintain
Outperform
Reason
Barrington analyst Michael Petusky raised the firm's price target on Anika Therapeutics to $16 from $15 and keeps an Outperform rating on the shares. The firm, which continues to think shares are "meaningfully undervalued," says "it appears that the company agrees" based on its recent decision to commence a $15M 10b5-1 share repurchase that it expects to complete by this June.
Barrington
Outperform
maintain
$20 -> $19
2025-05-12
Reason
Barrington
Price Target
$20 -> $19
2025-05-12
maintain
Outperform
Reason
Barrington Research
Michael Petusky
Buy
Maintains
$25 → $20
2025-03-13
Reason
Barrington Research
Michael Petusky
Price Target
$25 → $20
2025-03-13
Maintains
Buy
Reason
Barrington lowered the firm's price target on Anika Therapeutics to $20 from $25 and keeps an Outperform rating on the shares. Anika management reduced its previous adjusted EBITDA guidance for FY25, which had previously been forecast to be a double-digit margin but is now expected to be 8-10%, with pricing weakness in osteoarthritis pain management in the U.S. appearing to be the primary reason for the lowered outlook, the analyst tells investors.
See All Ratings
About ANIK
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What were the primary reasons for Anika's 27.42% stock drop?
How did the Hyalofast trial's missed endpoints impact investor confidence?
How might Anika's stock performance change following the legal investigation?
What could be the long-term financial implications of the trial's failure?